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The study of potentially effective drug therapies and mechanical 
devices for the prevention of restenosis after percutaneous coro-
nary revascularization has relied heavily on the use of experimen-
tal animal models. To date, >50 experimental studies have been 
reported and have suggested that at least nine different classes of 
pharmacologic agents inhibit the intimal proliferative response to 
arterial injury. However, no pharmacologic intervention has yet 
been shown to reproducibly reduce the incidence of restenosis 
after coronary balloon angioplasty in humans. 
To identify the reasons for the apparent nonspecificity of the 
animal models and to determine which model should most reliably 
predict the efficacy of individual therapies in humans, the distin· 
guishing characteristics of the experimental models were com-
pared. Particular attention was paid to the size and morphologic 
structure of the treated artery, the susceptibility of the species to 
spontaneous and diet-induced arterial disease, the nature of the 
Over the past decade, mechanical means of achieving per-
cutaneous coronary artery revascularization have been 
greatly refined. The majority of atheromatous coronary 
stenoses can now be successfully treated by balloon dilation, 
excisional atherectomy, endoluminal stenting or laser abla-
tion (1-4). The long-term efficacy of each of these proce-
dures remains limited, however, by recurrent stenosis at the 
site of intervention, which occurs in approximately 25% to 
35% of treated stenoses (2-4,5). This incidence ofrestenosis 
has proved to be refractory to a large number of pharmaco-
logic and mechanical interventions (6) and the histopathol-
ogy of the recurrent lesion appears to be independent of the 
nature of the injury inflicted on the arterial wall (7 ,8). As the 
number of percutaneous coronary interventions increases, 
the fiscal burden of recurrent coronary stenosis will climb. In 
1992, the number of coronary angioplasty procedures per-
formed in the United States is expected to be > 300,000. 
Even a moderate reduction in the incidence of restenosis 
could be expected to have a major impact on the cost of 
these procedures. It has been estimated, for example, that a 
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stimulus to intimal proliferation and several practical and logistic 
considerations. Finally, the reported efficacies of specific drug 
therapies in the respective animal models and in humans were 
compared. 
This review suggests that significant interspecies and occasion-
ally intraspecies differences do exist among the respective animal 
models, particularly in the extent and composition of the neoin-
timal thickening. These differences appear to reflect not only 
differences in the nature and extent of the arterial injury, but also 
intrinsic differences among the species in drug and lipid metabo-
lism and in the activity of the coagulation and fibrinolytic systems. 
These differences may account for the variability in sensitivity of 
these models to pharmacologic interventions and should be con-
sidered carefully in the interpretation of experimental studies of 
new devices and of apparently effective pharmacologic therapies. 
(JAm Coli Cardio/1992;19:418-32) 
reduction in the incidence of restenosis from 33% to 25% 
could result in annual savings of as much as $450 million (6). 
It follows that a considerable research effort into the 
pathophysiology of and preventive measures against reste-
nosis is urgently needed. However, clinical investigation of 
this entity has been impeded by several important limita-
tions. First, until recently, the inaccessibility of human 
coronary arteries has limited the potential for antemortem 
histopathologic analysis of postangioplasty recurrent steno-
ses. Now the excisional atherectomy catheter may provide 
valuable data regarding the cellular composition and im-
munocytochemical characteristics of the proliferative tissue 
at the site of prior interventions (7 ,9, 10). A second limitation 
has been the need for and cost of multicenter clinical trials of 
pharmacologic therapies in large numbers of patients. Anal-
ysis of the published findings of controlled clinical trials of 
treatment of restenosis suggests that the vast majority of 
these studies have lacked sufficient power to detect impor-
tant differences among potentially valuable therapeutic 
agents (11). A third limitation has been the need for complete 
angiographic follow-up in the study groups and a lack of 
consensus among investigators on the definitions of clinical 
and angiographic restenosis (6). 
These considerations highlight the need for a reliable 
experimental model for investigating the pathophysiology of 
restenosis and evaluating pharmacologic and mechanical 
means of preventing its occurrence. The principal aim of this 
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Figure 1. Histologic section of a human coronary 
artery showing restenosis due to intimal thickening 
12 months after coronary balloon angioplasty. Note 
the clearly visible dissection flap . 
review, therefore, is to examine the animal models that have 
been employed for this purpose and to consider whether any 
of these can be expected to reliably predict the impact of a 
given preventive measure on the incidence of restenosis in 
clinical trials. This will be approached by considering 1) the 
pathogenesis of human restenosis, 2) the distinguishing 
characteristics of each animal model, and 3) the reported 
efficacies of specific drug therapies in the respective animal 
models and humans. 
Pathophysiology of Human Restenosis 
The predominant mechanism by which balloon angio-
plasty relieves obstructive coronary stenosis appears to be 
by fracture through the atheromatous plaque, often with 
extension of a dissection plane into the muscular medial 
layer (12-21). A second mechanism may be stretching of less 
diseased segments of the arterial wall adjacent to an eccen-
tric, relatively nonelastic atheromatous plaque (22). The 
predominant mechanism for restenosis after balloon angio-
plasty is the formation of a fibrocellular neointima at the site 
of dilation. Postmortem studies (23,24) in patients who died 
several months after apparently successful coronary angio-
plasty clearly showed evidence of previous fracturing of the 
atheromatous plaque and medial dissection, with extensive 
neointimal proliferative tissue filling the crevices, overlying 
the plaque and obstructing the coronary lumen (Fig. l). In 
the latter investigation (24), immunoperoxidase studies 
showed no evidence of deposition of apolipoproteins in the 
neointima, suggesting that lipid deposition is not a significant 
pathogenic factor. In some patients, elastic recoil of over-
stretched, relatively disease-free segments of arterial wall 
may also cause recurrent stenosis without intimal prolifera-
tion (25,26). 
The factors that determine whether uncontrolled intimal 
proliferation and restenosis occur after balloon angioplasty, 
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stenting, laser ablation or atherectomy remain poorly under-
stood. It is generally believed that exposure of subintimal 
components of the vessel wall results in the deposition of 
platelets, thrombus formation and the release of growth 
factors from platelets, circulating monocytes, endothelium 
and, perhaps, smooth muscle cells themselves (5). These 
mitogens stimulate the transformation of medial smooth 
muscle cells from a resting contractile state to a synthetic 
phenotype and promote the proliferation of these cells and 
their migration from the media to the intima (27 ,28). Smooth 
muscle cell migration and proliferation are followed by the 
synthesis and secretion of extracellular connective tissue 
matrix, resulting in progressive lumen narrowing and ob-
struction to coronary flow. 
Restenosis and Atherogenesis 
This sequence of events from endothelial cell and medial 
injury to the formation of a fibrocellular neointima is be-
lieved to be very similar to that which occurs over a much 
greater time frame during the development of atherosclerotic 
plaques . The "response to injury" hypothesis for the devel-
opment of spontaneous atherosclerosis was first proposed by 
Virchow (29) and more recently modified by Ross (30). 
Considerable data accumulated largely from animal models 
(31-35) suggest that chronic dietary hypercholesterolemia is 
associated with progressive endothelial cell injury and the 
eventual formation of atheromatous lesions. Although sys-
tematic evaluation of the genesis of atherosclerotic plaques 
in humans is more difficult, these findings are consistent with 
the observations of several studies (36,37) that have shown 
that fatty streaks develop very early in normal children at 
sites that correspond to the location of atheromatous plaques 
in the adult arterial tree. 
Unifying hypothesis of vascular injury. The preceding 
observations suggest that early atherogenesis and restenosis 
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after balloon angioplasty may have a similar pathogenic 
mechanism. A unifying hypothesis was recently summarized 
by Ip et al. (38). Three grades of vascular injury were 
described. Type 1 injury results in no overt disruption of the 
endothelium, but rather a more subtle functional change in 
the integrity of the endothelial cells. Examples of this type of 
injury include chronic hypercholesterolemia (39) and injury 
induced by viral infection (40,41). Type 2 vascular injury, 
which results in endothelial denudation and intimal damage 
but no disruption of the internal elastic lamina or the 
muscular media, may occur during the early stages of 
formation of atheromatous plaques, during balloon arterial 
injury, in homocystinemia (42) and by immunologically 
mediated mechanisms (43-45). Type 3 injury, which disrupts 
not only the endothelium but also the internal elastic lamina 
and media, is the predominant injury induced by balloon 
angioplasty, coronary atherectomy, laser ablation and endo-
vascular stenting. This type of injury may also occur spon-
taneously in complicated atherosclerotic plaques and as a 
consequence of increasing age (46). Under this classification 
of vascular injury, coronary artery restenosis along with 
coronary vein graft and cardiac allograft atherosclerosis can 
be considered to represent a much accelerated form of the 
same pathogenic process that results in spontaneous ather-
osclerosis. 
Characteristics of Animal Models 
of Restenosis 
Several factors need to be considered in comparing the 
respective animal models. These include factors relating to 
1) the arterial substrate itself; 2) the nature of the arterial 
injury; and 3) several practical and logistic considerations. 
Arterial substrate. Ideally, the arterial bed of the animal 
species chosen should have a size and structure that are 
histologically and biochemically similar to those of human 
coronary arteries. The basic morphologic structure of mam-
malian arteries appears to be very similar in all species 
examined. In elastic arteries such as the thoracic and ab-
dominal aortas and the carotid and iliac arteries , a repeating 
medial lamellar unit, originally described by Wolinsky and 
Glagov (47), is present in all major vertebrate classes with 
only minor variations (48). The number of lamellar units in 
the media of the adult mammalian aorta is proportional to the 
radius of the artery, and the average tension per lamellar unit 
is remarkably constant, regardless of age and species (47). In 
contrast, the amount of elastin in the media of coronary 
arteries, which are by definition muscular arteries, varies 
with the size of the animal. The elastin content of the dog, 
pig and baboon coronary artery is very similar to that of the 
human coronary artery and greater than apparent in smaller 
species including rodents and fowl (49). The thickness of the 
arterial intima also varies among species. In smaller animals 
including rats and rabbits, the subendothelial space between 
the endothelium and internal elastic lamina is very narrow 
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and virtually acellular. A similar intimal structure is only 
present in the larger arteries of humans during fetal and early 
neonatal life (46). Thereafter, the space becomes progres-
sively thicker because of infiltration of smooth muscle cells 
and the development of a musculoelastic layer consisting of 
elastic tissue, collagen and scattered smooth muscle cells. 
These age-related changes are also observed in the larger 
mammals such as the nonhuman primates and swine. 
A second consideration is the susceptibility of the se-
lected species to spontaneous or diet-induced atherosclero-
sis that morphologically and topographically resembles hu-
man atherosclerosis. This characteristic not only permits the 
evaluation of pharmacologic and mechanical therapies in 
diseased arteries, but also suggests that the intimal response 
to injury and its susceptibility to interventions may mimic 
the response seen in humans. Additional factors that may be 
relevant to the study ofrestenosis include whether the artery 
is or is not diseased at the time of injury, the nature of the 
underlying disease process (for example, foam cell infiltra-
tion vs. fibrocellular thickening), the age (and perhaps gen-
der) of the animal and the presence or absence of concomi-
tant hypercholesterolemia. 
Arterial injury. Models employed to date have used a 
variety of endarterial injuries to induce intimal proliferation. 
These injuries may vary in the extent to which they stimulate 
a proliferative response. Factors to be considered in com-
paring the models include the severity of the injury (in 
particular, whether the internal elastic lamina is disrupted 
and the extent of injury to the underlying media), the platelet 
response and formation of thrombus at the site of injury and 
rheologic factors including the presence of adjacent arterial 
stenoses, branch points, changes in vasomotor tone and 
blood flow disturbances. 
Practical considerations. These include the size of the 
animal and the selected artery, the availability of ready 
access to the arterial tree, the time course of the develop-
ment of intimal proliferation, the cost and procurability of 
the animal, the cost of its housing and feeding, potential 
difficulties in its handling, the robustness of the animal 
species and its potential for disease transmission. The need 
for fluoroscopic imaging is also a limiting factor in some 
models. 
Specific Animal Models 
Several animal species have been used to investigate the 
pathogenesis of atherosclerotic disease (50-52). Many of 
these models are also useful for the study of restenosis. In 
contrast, avian models of atherosclerosis are not practical, 
principally because of the size and shape of the avian thorax, 
but also because of differences in cardiopulmonary dynamics 
and widespread involvement of small intramural coronary 
arteries in the disease process (50). For these reasons, avian 
models will not be further considered and discussion will be 
confined to mammalian species and consideration of in vitro 
studies by cell culture. 
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Table 1. Characteristics of Animal Species 
Life Span Onset of Fertility 
Species (yr) (months) 
Rat 2-4 2 
Rabbit 
New Zealand 6-13 6-8 
WHHL 3-5 6-8 
Dog 13-25 6-8 
Primates (Rhesus) 10-30 24-36 
Swine 
Domestic pig 15-25 5-8 
Minipig 15 4-5 
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Adult Weight Purchase Price* Per Diem Costt 
(kg) ($) ($) 
0.2-0.4 12-20 0.5-0.75 
4-4.5 170 1.76 
3-4 250 1.76 
15-25 189 3.2-5.95 
2-12 2,300-3 ,000 4.94-6.14 
200-400 120 6.95 
20- 40 420 6.95 
*Including freight charges; tcurrent University of Michigan charges (normolipidemic diet) . WHHL = Watanabe 
heritable hyperlipidemic rabbit. 
Rats 
Response to arterial injury. Although some inbred strains 
are susceptible to spontaneous or diet-induced arterial dis-
ease (53,54) , rats are generally considered to be relatively 
resistant to atherogenesis (51 ,55). Moreover, rat arteries 
differ morphologically from human arteries in that they have 
no vasa vasorum, have a very much thinner subintimal layer 
and have a relatively small elastin content in the media 
(49,55). Despite this, the response of the rat arterial wall to 
injury is one of the most thoroughly investigated of any 
animal species. The principal advantages of the rat model are 
that the animals are readily available, easy to handle and 
inexpensive to purchase and maintain (Table l) and they 
develop a very predictable and rapid proliferative response 
to several forms of endarterial injury including air drying and 
balloon denudation (56-63). Interestingly, endothelial de-
nudation using a fine nylon filament that does not damage the 
arterial media induces only a minor smooth muscle cell 
proliferative response (64,65). The use of air drying to cause 
extensive endothelial damage in the rat carotid artery was 
first described by Fishman et al. (56). Although this model 
does not mechanically deform the arterial wall and does not 
cause any overt damage to the underlying medial smooth 
muscle, a dense layer of platelets rapidly forms over the 
denuded segment and intimal thickening due to smooth 
muscle cell proliferation occurs within 14 days to a thickness 
of approximately three times that of the media (56,57). At 
later stages, a progressive decrease in thickness of the 
neointima occurs as a result of a decrease in the number of 
cells present and an increase in the density of the associated 
connective tissue stroma (56). 
The rat carotid artery balloon injury model. Balloon 
dilation and endothelial denudation of the rat carotid artery 
(Fig. 2A), a modification of the aortic balloon injury model of 
Baumgartner (58) , has been systematically evaluated by 
several investigators (59-63). The passage of a Fogarty 
catheter along the length of a rat carotid artery is followed by 
a well defined series of events similar to that described in the 
model of Fishman et al. (56). Endothelial denudation is 
promptly followed by platelet adhesion and endothelial and 
smooth muscle cell proliferation (59). The majority of the 
proliferating smooth muscle cells enter the growth cycle 
between 24 and 72 h after injury (59) and begin to migrate 
from the media into the intima. Approximately 50% of the 
migrating cells do not divide but nonetheless contribute to 
the increasing cellularity and thickness of the intima (60) . 
Neointimal thickness peaks approximately 3 weeks after 
injury and remains relatively constant thereafter despite 
continuing cell proliferation. Several studies (59,61) have 
suggested a critical relation between the intact endothelium 
and medial smooth muscle cell proliferation. Regrowth of 
the rat endothelium ceases after approximately 6 weeks and 
may leave a large central area devoid of endothelium. 
Proliferation of the smooth muscle cells underlying these 
denuded sites may continue at rates of up to 50 times greater 
than control rates for periods of > 12 months (62). Interest-
ingly , recent studies (66) have shown that rat carotid endo-
thelial cells that have ceased replicating after balloon injury 
can be stimulated to recommence replication and cover the 
remaining denuded surface by the systemic administration of 
basic fibroblast growth factor , a potent endothelial mitogen 
and angiogenic factor. 
The rat carotid artery model has also been used to 
evaluate the influence of a variety of physiologic changes on 
the extent of intimal proliferation after balloon endothelial 
denudation. For example , hypophysectomy 2 weeks before 
balloon denudation of the rat aorta has been shown (67) to 
completely inhibit the smooth muscle cell proliferative re-
sponse without interfering with regrowth of the endothelium. 
In vitro studies (68) have suggested that this effect is 
mediated through the influence of pituitary growth hormone 
on the release of somatomedin C. A second physiologic 
variable examined in the rat model is the influence of age on 
endothelial and smooth muscle cell proliferation. The rate of 
normal cell replication appears to be highest in the neonatal 
period (69) and in cell culture, immature cells proliferate in 
response to a stimulus sooner than do cells from older 
animals (70). In vivo studies (71) suggest that although the 
smooth muscle cell proliferative response to endothelial 
denudation is indeed delayed in older animals, the response 
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Figure 2. Intimal proliferation after balloon injury of a rat carotid artery. Reprinted 
from Powell et al. (142) with permission of the American Association for the 
Advancement of Science. B, Intimal proliferation after balloon angioplasty of a 
stenosed iliac artery in a hypercholesterolemic rabbit. Note the previous intimal 
dissection and marked neointimal thickening due to foam cell infiltration. Reproduced 
courtesy of Dr. David P. Faxon. C, Intimal thickening after balloon dilation of a 
normal porcine carotid artery. The neointima is eccentric and maximal at the site of 
disruption of both the internal and external elastic laminae. The fibrocellular neointima 
contains a large number of hemosiderin-Iaden macrophages. D, Marked coronary 
stenosis due to neointimal thickening 4 weeks after implantation of an oversized metallic 
stent in a normal porcine coronary artery. The stent wires penetrated both the internal 
and external elastic laminae. 
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in these animals may be more extensive and more sustained. 
Thus, the age of animals in restenosis studies may have an 
important influence on the severity of the proliferative 
response. 
Rabbits 
On a normal vegetarian diet, most strains of rabbit do not 
develop spontaneous atherosclerosis, but may develop de-
generative lesions in the arterial media that resemble Moncke-
berg's medial sclerosis (72). In contrast to the rat, however, 
the rabbit appears to be highly susceptible to the develop-
ment of intimal lesions when exposed to extremely high 
levels of serum cholesterol (51). Sustained levels of choles-
terol >2,000 mg/dl can be readily achieved by diet alone. 
This extreme hypercholesterolemia may result from an in-
herently poor catabolic system for cholesterol (73) and is 
associated with widespread cholesterol deposition in the 
reticuloendothelial system, causing hepatic, splenic and 
lymph node enlargement, features that are more typical of a 
lipid storage disease than atherosclerosis. Lesions that de-
velop in the intima of the aorta and great arteries are 
composed predominantly of lipid-laden macrophages (foam 
cells) and rarely display the features of advanced atheroscle-
rotic plaque, such as calcification, central necrosis, ulcer-
ation and thrombus formation. More typical atherosclerotic 
plaques occur in animals fed an intermittent hypercholes-
terolemic diet (50), in those fed a moderately hyperlipidemic 
diet after initial arterial injury (74,75) and in certain breeds of 
rabbit that lack membrane receptors for low density lipopro-
tein (homozygous Watanabe heritable hyperlipidemic rabbit) 
(76). 
Balloon denudation of aortic iliac arteries. The use of the 
rabbit as an experimental model for balloon angioplasty was 
first described by Block et al. (77), and the long-term effects 
of balloon dilation in the atherosclerotic rabbit were later 
described by Faxon et al. (78). In these studies, stenotic 
lesions consisting principally of concentric foam cell infiltra-
tions of both the intima and media were initially induced in 
the aorta and iliac arteries by balloon endothelial denudation 
followed by a 6- to 12-week period of feeding with a 
2%-cholesterol diet. Dilation of these lesions resulted in 
rupture of the neointima with platelet deposition and fibrin 
formation (77) and subsequent restenosis at the site of 
balloon angioplasty (78). Histologic evaluation 4 weeks after 
angioplasty showed marked concentric reduction in the 
arterial lumen as a result of the formation of a loose, 
relatively acellular, lipid-rich, edematous connective tissue 
layer that filled the spaces created by rupture of the intima 
(Fig. 2B). Organized thrombus was apparent in approxi-
mately half of the animals. 
The major advantages of the atherosclerotic rabbit iliac 
artery model are that the animals are easily handled and 
inexpensive, breed readily and reliably develop restenosis 
(Table 1). In addition, unlike the rat carotid artery and aorta, 
the adult rabbit iliac artery is approximately the same size as 
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the human coronary artery. The model may be useful, 
therefore, for the evaluation of new percutaneous revascu-
larization devices (79-82). However, the major difference in 
consistency and composition of the obstructive material in 
the hypercholesterolemic rabbit from that of human ather-
oma suggests that direct extrapolation of the efficacy of drug 
therapies and devices in this model should be undertaken 
with caution. Thus, the principal disadvantage of the hyper-
cholesterolemic rabbit model is the prominent involvement 
of lipid not only in the initial plaque, but also in the 
restenosis lesion. In addition, rabbit iliac arteries are highly 
vasoreactive and have multiple side branches. An alternative 
model that produces iliac stenoses with a consistency more 
equivalent to that of human atheroma uses a chronically 
indwelling arterial catheter (74). Whether this or the ho-
mozygous Watanabe heritable hyperlipidemic rabbit will 
provide better models of re stenosis remains to be evaluated. 
Balloon dilation of the normal rabbit iliac artery also 
results in a considerable smooth muscle cell proliferative 
response. Although this model has not been widely used to 
evaluate pharmacologic means of preventing restenosis, it 
has been used to examine the physiologic effects of balloon 
dilation, such as the relation between intimal thickening and 
chronic impairment of endothelial-dependent arterial relax-
ation (83,84). 
Dogs 
Like all natural carnivores, the dog is very resistant to 
diet-induced atherosclerosis. In fact, arterial lesions rarely 
develop unless the animal is made simultaneously hypothy-
roid by thyroidectomy or the administration of antithyroid 
drug therapy (51,85). The vessels that are first affected in 
thyroid-suppressed hypercholesterolemic dogs are predom-
inantly small arteries including the thyroid, iliac, intercostal 
and carotid arteries, rather than the larger vessels more 
commonly involved in humans. Coronary arteries become 
diseased late in the process. A second important difference 
from human atherosclerosis is the predominance of medial 
rather than intimal thickening and lipid accumulation. An 
additional factor that may confound the interpretation of 
drug studies in dogs is the considerably greater activity of 
the fibrinolytic system in these animals. Circulating plasmin 
is often detectable in dogs (but not in humans) and fibrinogen 
levels may fluctuate widely in the postoperative period (86). 
The activity of the fibrinolytic system at rest and in response 
to injury may be of great relevance because clinical studies 
(87) have suggested that fibrinolytic capacity may be im-
paired in patients who develop restenosis after coronary 
balloon angioplasty. 
Extent of intimal proliferation after arterial injury in the 
canine model. Despite these limitations, dogs have been 
commonly used as experimental models, principally because 
of the similarity in size between the coronary arteries of 
adult dogs and those of humans, the ready availability and 
low cost of procuring and keeping the animals and the ease 
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of vascular access (Table 1). Relatively few data are avail-
able on the extent of intimal proliferation after arterial injury 
in the canine model. In a recent study of balloon angioplasty 
of normal canine renal arteries, Orlandi et al. (88) observed 
that mural deoxyribonucleic acid (DNA) synthesis increased 
in the balloon-dilated segments 5 days after injury and 
persisted for :2:2 weeks. This study and others (89,90) noted 
only a mild intimal proliferative response but prominent 
proliferation of the vasa vasorum and the adventitia. The 
latter finding has also been observed in association with 
human atherosclerotic disease (91), but its role in the patho-
genesis of atherosclerosis and restenosis is at present un-
clear. Interestingly, moderate intimal proliferation (seen in 
association with disruption of the internal elastic lamina) has 
been reported (92) after external freezing of normal canine 
arteries, an observation in keeping with the concept that 
smooth muscle cell proliferation and intimal thickening are a 
nonspecific response to arterial wall injury. 
Evaluation of interventional devices. The most common 
use for the canine model has been in the evaluation of 
interventional devices including coronary stents, laser cath-
eters and atherectomy devices (93-96). The insertion of an 
appropriately sized endovascular metallic stent results in the 
formation of a fine layer of thrombus, followed by rapid 
growth of a layer of endothelial and smooth muscle cells that 
cover the stent struts (93 ,94). The neointima reaches a 
maximal thickness of 200 to 300 JLm approximately 8 weeks 
after stent insertion and thereafter becomes progressively 
thinner over a period of 6 to 9 months (93) . Similar changes 
have been observed after the implantation of porous vascu-
lar prostheses (86). In contrast to the thick neointima that 
develops in the pig, the surface of the prosthesis becomes 
covered with a thin smooth layer of neointima within 8 to 12 
weeks of implantation in the dog. These findings suggest that 
the canine arterial wall may be relatively nonreactive to 
acute or chronic injury and, for this reason, extrapolation of 
the results of interventions in normal canine coronary arter-
ies to diseased human arteries may be particularly difficult. 
Clearly, because of the difficulties in inducing atheroscle-
rotic disease, the dog is not a good model for the evaluation 
of interventional devices in diseased arteries. One means of 
overcoming this limitation may be the use of an interposition 
graft of human atherosclerotic coronary or peripheral artery 
anastomosed proximally and distally to a normal canine 
femoral artery (97). 
Nonhuman Primates 
Spontaneous atherosclerosis has been reported in several 
species of nonhuman primate and in general the sequence of 
events and the topography of the lesions are similar to those 
observed in humans (50-52). However, a broad spectrum of 
species-dependent changes has been described. The most 
susceptible species is the rhesus monkey (Macaca mu/atta), 
in which atherosclerotic plaques develop in the aorta and 
carotid, iliac and coronary arteries, both spontaneously over 
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a period of several years and in association with a hyper-
cholesterolemic diet (98). The changes seen resemble the 
features of advanced human atheroma including central 
medial necrosis, ulceration, calcification and thrombosis. In 
some species, atherosclerotic gangrene and fatal myocardial 
infarction have also been recorded (50). Relatively little has 
been published, however, on the intimal proliferative re-
sponse to arterial injury in nonhuman primates. As might be 
expected from the spectrum of atherosclerotic lesions seen, 
it does appear that the nature and extent of the proliferative 
response are both species and diet dependent. Balloon 
injury, for example, stimulates a predominantly fibromus-
cular intimal lesion in some species, particularly when 
performed in conjunction with a diet supplemented with 
peanut oil (52). In contrast, other species, particularly when 
fed a high fat, cholester-ol-rich diet, may develop concentric, 
transmural , lipid-rich proliferative lesions (52). Compound-
ing this intraspecies difference in response to injury are the 
practical limitations of nonhuman primates as models of 
human atherosclerosis or restenosis (Table 1). Not only are 
the animals expensive to obtain and maintain, but also they 
are highly susceptible to disease and death in captivity and 
are uncooperative and difficult to handle. 
Swine 
Spontaneous and diet-induced atherosclerosis. Of all the 
animal species systematically examined to date, the pig is 
most similar to humans in its cardiovascular morphology and 
physiology and susceptibility to atherosclerosis. The coro-
nary arteries of the adult pig approximate the size of human 
coronary arteries and have a very similar morphologic 
structure (99). The animals appear to be susceptible to both 
spontaneous and diet-induced atherosclerosis. Pigs are om-
nivorous and readily consume a human diet. In pigs on a free 
range, unsupplemented diet, atherosclerotic lesions develop 
within 4 to 8 years. The distribution and morphology of these 
lesions closely resemble those observed in humans, as does 
the sequence of events from lipid deposition and foam cell 
formation to fibrocellular proliferation and calcification 
(50,51,100). Although both cerebral and myocardial infarc-
tion have been observed in aged swine, the features of 
complicated atheroma including ulceration, thrombosis and 
plaque hemorrhage are uncommon in spontaneous porcine 
atherosclerosis (100). The development of widespread ather-
omatous disease can be accelerated in domestic swine by 
dietary manipulation. In contrast to nonhuman primates, 
pigs fed a diet supplemented with a high content of saturated 
fats quickly develop changes in the serum lipid profile that 
mimic the changes seen in humans. These include markedly 
elevated serum cholesterol, elevated low density lipopro-
teins, a reversal in the ratio of high to low density lipopro-
teins (from > 1 to <1) and evidence of activation of coagu-
lation system proteins (101). A further important difference 
from the nonhuman primates is that these changes and the 
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susceptibility to atherogenesis do not appear to be species or 
gender dependent. 
Although the domestic pig fulfills many of the criteria for 
the ideal model of atherosclerosis, its use for this and as a 
model for restenosis has been limited by one major factor. 
Although the animals are readily available and relatively 
inexpensive to purchase, they grow rapidly and may reach 
weights >400 kg (Table 1). The cost of maintaining such 
animals and the logistic difficulties involved in transporting 
and handling them make them unsuitable for long-term 
investigations. This problem has been largely overcome by 
using selectively bred strains of miniature swine, some 
varieties of which reach a maximal weight of only 20 to 40 kg 
(102-106). In adulthood, these animals develop atheroscle-
rotic lesions that are indistinguishable from those of larger 
domestic pigs and very similar to the complex lesions typical 
of advanced human atherosclerosis. The disease process can 
be considerably accelerated in selected arteries by using a 
combination of mechanical injury and diet-induced hyper-
cholesterolemia (104,107). Although these special breeds of 
pig are more expensive than domestic swine (and are not as 
readily available), the costs of feeding the latter increase 
progressively so that the cumulative costs of acquiring and 
maintaining a farm pig may be greater than that for miniature 
swine for investigations that last >2 or 3 months (107). 
Balloon injury of the normal porcine artery. The events 
that follow balloon angioplasty of the normal porcine artery 
were investigated by Steele et al. (108). Dilation of the 
carotid artery using an oversized balloon (balloon/artery 
ratio approximately 1.5: I) resulted in complete endothelial 
denudation, marked platelet deposition and thrombus forma-
tion, dissection through the internal elastic lamina into the 
arterial media and necrosis of medial smooth muscle cells. 
Intimal thickening due to smooth muscle cell proliferation 
was apparent 7 days after injury and reached a mean 
maximal thickness of 85 11-m at 14 days. Other studies (109) 
using the same model have shown that arterial balloon 
dilation is a considerably stronger stimulus to smooth muscle 
cell proliferation than is endothelial denudation alone despite 
a similar degree of platelet deposition. Our own observations 
using this model suggest a critical role for disruption of the 
internal elastic lamina in the stimulation of intimal thicken-
ing. The lesions that occur after balloon injury of the porcine 
carotid artery are commonly eccentric and overlie breaches 
in the internal elastic lamina (Fig. 2C). The remainder of the 
circumference ofthe arterial lumen, although exposed to the 
same pressure and degree of stretch, may be free of any 
apparent proliferative response. In this model, thrombus 
may play a more prominent role in the composition of the 
neointima than in some other models. This is, however, 
consistent with recent observations from histologic analysis 
of tissue retrieved by coronary atherectomy (110) or after 
stent implantation (28), which suggest that thrombus may 
play a more important role in the pathophysiology of human 
restenosis than had been previously appreciated. 
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Endoluminal stenting of normal coronary arteries. An 
alternative means of creating a controlled, chronic arterial 
injury is endoluminal stenting. Although implantation of 
appropriately sized, balloon-expandable metallic stents in 
porcine coronary arteries results in only a moderate degree 
of intimal thickening (Ill), the use of endovascular stents 
oversized by approximately 30% to 50% has been reported 
by several investigators to stimulate considerable intimal 
thickening both in normal porcine coronary arteries 
(112, 113) and in animals with diet-induced atherosclerosis 
(114, 115). This appears to be a very effective means of 
promoting smooth muscle cell proliferation and concentric 
intimal thickening, whose histologic appearance is very 
similar to that of the proliferative neointimal tissue of human 
restenosis (112) (Fig. 2D). It has the advantage of allowing 
dilation of the coronary arteries and focal disruption of the 
internal elastic lamina and media without the risk of acute 
closure and intractable ventricular fibrillation. Further char-
acterization of this model is required, however, to better 
define the relative contributions of smooth muscle cell 
proliferation, thrombus formation and foreign body inflam-
matory reaction as principal components of the neointima. It 
is possible that this model may provide too great a stimulus 
to smooth muscle cell proliferation and that the pig may be 
too susceptible to this form of injury to permit evaluation of 
potentially valuable drug therapies. Unlike dogs and hu-
mans, in pigs, synthetic grafts rapidly and completely be-
come endothelialized and subsequently develop a thick, 
often calcified capsule lining the lumen surface. This re-
sponse is not dependent on the age, gender or strain of the 
pig, suggesting that these variables may be less important in 
this model than in other animal species (86). 
Lessons From Cell Culture 
Considerable progress in the understanding of vascular 
biology has been made from the in vitro study of endothelial 
and vascular smooth muscle cells. Several primary cell 
culture systems have been described (116). In one system, 
proteolytic enzymes such as collagenase and elastase are 
used to release individual medial smooth muscle cells from 
the underlying arterial substrate. Cells obtained using this 
method initially have the morphologically well differentiated 
appearance of the contractile phenotype. After a quiescent 
period of several days, the cells undergo a phenotypic 
change characterized by an increase in cytoplasmic or-
ganelle density and a decrease in contractile elements (70). 
This change is accompanied by proliferation of the cells until 
they become confluent, at which time the increased mitotic 
activity ceases. If the initial cell seeding is sufficiently dense 
to allow a confluent monolayer of cells to form within five 
population doublings and 5 to 7 days of the original change in 
phenotype, the cells typically revert to the contractile state. 
Conversely, if the cells are initially seeded sparsely, they 
typically remain in the synthetic phenotype after confluence 
has been achieved (70). A second culture system (116) uses 
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Table 2. Comparison of Arterial Size and Susceptibility of Animal Species to Atherosclerosis 
Arterial Diameter (mm) 
Susceptibility to 
Species Coronary Peripheral Atherosclerosis 
Rat 0.08-0.2 Aorta 2; carotid I Resistant 
Rabbit 
New Zealand 0.1-0.4 Aorta 6; iliac 2-3 Dietary cholesterosis 
WHHL 0.1-0.3 Aorta 5; iliac 2-3 Rapid, spontaneous 
Dog 0.7-2.5 Aorta 15; femoral 2-4 Resistant 
Primates 0.6-2.5 Aorta 6-10 Variable 
Swine 
Domestic pig 1-2.5 Aorta 18-24; carotid 3-5 Similar to human 
Mini peg 1-2.5 Aorta 15-18; carotid 2-3 Similar to human 
WHHL = Watanabe heritable hyperlipidemic rabbit. 
substrate-attached explants from arterial media. Cell out-
growth from the explant begins after approximately 1 week 
and the cells tend to retain a synthetic phenotype, even when 
mitotic activity returns to normal (116). 
lp vitro studies of response of endothelial and smooth 
muscle cell interactions. Cell culture techniques have be-
come an increasingly important means of studying the be-
havior of individual components of the arterial wall. In vitro 
studies have highlighted interspecies differences in the re-
sponse of endothelial and smooth muscle cells to a variety of 
stimuli. Adult rat aortic smooth muscle cells, for example, 
undergo a more rapid change in phenotype and begin to 
proliferate earlier than adult rabbit or pig cells (70). Cell 
culture studies have also proved valuable for the comparison 
of the growth kinetics of smooth muscle cells from normal, 
atherosclerotic and restenosing human arteries (9,117), in-
vestigation of interactions between the constituent cells of 
normal and atherosclerotic arteries (69, 118), investigation of 
factors that control cell migration (119) and cell adhesion to 
extracellular connective tissue matrix (120) and evaluation of 
cellular proliferative and metabolic responses to endogenous 
and exogenous mitogens and chemotactic factors (5,30,121-
123). Interpretation of the results of these studies and their 
extrapolation to the clinical situation are clearly limited by 
their isolation from the complex interactions that occur in 
vivo. Nonetheless, in addition to helping unravel the intri-
cate series of events that characterize the intimal prolifera-
tive response to arterial injury, cell culture techniques may 
prove to be useful as a screening system for the development 
and evaluation of pharmacologic agents that inhibit smooth 
muscle cell proliferation and the synthesis of extracellular 
matrix without interfering with regrowth of the disrupted 
endothelium. 
Pharmacologic Prevention of Restenosis in 
Animal Models 
A principal aim of this review is to compare the predictive 
accuracy of the commonly used animal models of human 
restenosis. Such an undertaking requires a brief consider-
ation of several statistical issues that are relevant to both 
experimental animal and clinical restenosis studies. The 
overwhelming majority of clinical pharmacologic studies 
reported to date have failed to show a significant reduction in 
the incidence of restenosis (6). With few exceptions, how-
ever, these studies have lacked the power to detect a 
moderate therapeutic effect of the drug therapy. To detect a 
33% reduction in the restenosis rate (assumed to be 30% in 
placebo-treated patients) at a significance level of p < 0.05 
with a power of 0.8, a randomized trial needs to enroll 320 
patients with an angiographic follow-up rate of 100%. To 
detect a 25% reduction with the same degree of confidence, 
596 patients with complete follow-up would be required. To 
date, however, only one published randomized study (124) 
has recruited >500 patients. The potential for false negative 
studies (type 11 error) also exists in experimental studies. Far 
fewer animals are required than in clinical trials, however, 
because histologic examination allows measurement of 
neointimal thickness as a continuous rather than a dichoto-
mous variable and because complete follow-up is always 
possible. Of more concern in experimental studies is the 
consistency of the response to injury. The more predictable 
the severity of the inflicted injury and the extent of neointi-
mal thickening in response to the injury, the fewer animals 
are required and the greater is the statistical power of the 
study. Some models of vessel wall injury may result in a 
regionally variable degree of arterial trauma. Ideally, in 
these models, some means of correcting the degree of intimal 
thickening for the local extent of mural injury should be 
performed. 
From the preceding discussion, it is clear that there are 
major differences among the animal models, particularly in 
terms of the nature of the arterial injury and the composition 
of the neointima. It could be expected, therefore, that a 
pharmacologic therapy that is effective in one animal model 
may be ineffective in another animal species or in humans. 
This has, indeed, been the experience with several classes of 
pharmacologic agents (Table 3) . 
Heparin. The agent that has been most extensively eval-
uated in animal models is heparin. In vitro studies (70) have 
suggested that a heparin-like glycosaminoglycan elaborated 
from endothelial cells maintains medial smooth muscle cells 
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Table 3. Pharmacologic Interventions in Animal Models and Humans 
Drug Therapy Cell Culture Rat Carotid Rabbit Iliac Pig Human 
I. Antithrombin agents 
Heparin + (70,125) + (126-130) + (131) 0 - (132) 
Hirudin 0 0 + (133) 0 0 
2. Antiplatelet agents 
Aspirin 0 - (138) + (134,137) - (112) - (139,140) 
Other 0 - (137) + (136,137) - (165) - (166) 
3. Calcium channel blockers 
Nifedipine 0 + (141) + (141) 0 - (144) 
Verapamil 0 ± (141,142) 0 0 - (146) 
Diltiazem 0 + (141) 0 0 - (145) 
4. ACE inhibitors 
Captopril 0 + (142) 0 0 0 
Cilazapril 0 + (142) + (148) - (149) 0 
5. Immunosuppressive agents 
Steroids + (150) 0 + (151) 0 - (124) 
Cyclosporine 0 + (167) - (168) 0 0 
6. Antimitogenic agents 
Colchicine + (152) 0 + (153) 0 - (154) 
Other + (169) 0 + (170) - (171) 0 
7. Fish oils + (172) 0 + (173) 0 ± (174,175) 
8. Growth factor antagonists 
Angiopeptin + (159) + (159) + (159) 0 0 
Trapidil + (155) + (156) + (157) 0 + (158) 
9. HMG-Co A reductase inhibitors 
Lovastatin + (161 , 162) 0 + (163) 0 + (164) 
The numbers in parentheses indicate the cited study reference. 0 = no study reported; - = therapy ineffective; + = positive results reported; ± = both 
positive and negative results reported. 
in the contractile phenotype and inhibits smooth muscle cell 
proliferation. The growth-inhibitory effect of heparin on 
quiescent smooth muscle cells in vitro is 50- to lOO-fold 
greater than its effect on proliferating cells (125). It appears 
to act by inhibition of cell transition from the prereplicative 
phase (Gl) to the phase of DNA synthesis (S phase) and can 
be added as late as 12 to 18 h after stimulation without 
reduction in its antiproliferative activity (126,127). In vivo 
studies (128-130) have consistently shown heparin to be 
effective by several routes of administration in the rat carotid 
model (at doses of 50 to lOO U/kg per h) and in the 
atherosclerotic rabbit iliac artery model (131). The inhibitory 
activity of heparin in these models does not appear to 
depend on its anticoagulant activity because the nonantico-
agulant subfraction of heparin is equally as effective as 
heparin with anticoagulant activity (128, 131). In contrast, 
intravenous heparin titrated to a partial thromboplastin time 
1.5 to 2.5 times normal (approximately 10 to 16 U/kg per h) 
and given for 18 to 24 h after uncomplicated angioplasty was 
ineffective in the prevention of restenosis after balloon 
angioplasty in humans (132). It is possible that more pro-
longed infusions, higher systemic doses of nonanticoagulant 
heparin or the use of high concentration local therapy may 
prove to be more effective in clinical studies; one random-
ized, placebo-controlled 400-patient study of low molecular 
weight heparin (enoxaparin) in a dose of 40 mg/day subcu-
taneously for 28 days has recently completed enrollment. 
Alternatively, other more potent thrombin inhibitors may 
prove to be effective in clinical studies. In one study (133), 
for example, intravenous recombinant hirudin was more 
effective than heparin in preventing recurrent stenosis after 
balloon angioplasty in atherosclerotic rabbit iliac arteries. 
Antiplatelet therapy. The role of platelets and platelet-
derived mitogenic factors in the genesis of atherosclerosis 
and restenosis has been much debated. Friedman et al. (134) 
noted suppression of the intimal proliferative response to 
balloon injury in severely thrombocytopenic rabbits. Other 
investigators have noted a reduction in the susceptibility of 
swine with von Willebrand's disease to atherosclerosis in-
duced by atherogenic diet alone (135) or dietary manipula-
tion and balloon endothelial injury (136). In animal models of 
restenosis, however, antiplatelet therapy has been inconsis-
tent in its efficacy (Table 3). Although Faxon et al. (137) 
observed a reduction in the incidence and severity of recur-
rent stenosis in the atherosclerotic rabbit model in animals 
treated with sulfinpyrazone or aspirin and dipyridamole, 
antiplatelet therapy was not effective in the rat carotid model 
(138) or stented atherosclerotic porcine coronary model 
(115). In the study of Clowes et al. (138), although the 
antiplatelet agents (aspirin, reserpine and flurbiprofen) effec-
tively inhibited in vitro platelet aggregation, platelet adhe-
sion to the denuded rat endothelium was unaffected. Be-
cause cyclooxygenase inhibitors such as aspirin block only 
thromboxane A2-mediated platelet aggregation, it is possible 
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that more potent antiplatelet therapy directed, for example, 
at the platelet glycoprotein lib/Ilia receptor may be required 
to prevent smooth muscle cell proliferation. This may ex-
plain the Jack of impact of standard antiplatelet therapy on 
the incidence of restenosis after balloon angioplasty in 
clinical studies (139,140). 
Calcium channel antagonist therapy. Several calcium 
channel antagonists have been evaluated in animal models of 
restenosis. Jackson et al. (141) noted a reduction in DNA 
synthesis after aortic balloon injury in rats treated with 
nifedipine, verapamil, diltiazem or Janthan!Jm. Nifedipine 
(10 mg/kg, orally two times a day) was aiso effective in 
reducing aortic neointimal formation in normolipidemic rab-
bits 14 days after balloon injury. In contrast, in other studies, 
verapamil (100 mg/kg per day) was ineffective in preventing 
intimal proliferation in the rat carotid artery (142) and 
nisoldipine (20 mg/day) was ineffective in preventing reste-
nosis in the atherosclerotic rabbit iliac artery (143). Although 
calcium channel antagonists are widely used clinically in the 
postangioplasty period, data from clinical trials have also 
been conflicting. Whereas two relatively small, randomized, 
angiographically controlled trials (144,145) showed no reduc-
tion in the incidence or severity of restenosis with calcium 
channel blocker therapy, preliminary results from an equally 
small study (146) suggested a beneficial effect of oral vera-
pamil. 
Angiotensin-converting enzyme inhibitors. After prelimi-
nary studies (147) suggesting that a local angiotensin system 
may regulate the vascular response to endothelial injury, 
Powell et al. ( 142) examined the effects of very high doses of 
the angiotensin-converting enzyme inhibitors cilazapril 
(10 mg/kg per day) and captopril (100 mg/kg per day) on 
neointimal proliferation in the rat carotid artery. Both agents 
were highly effective and concomitant heparin therapy ap-
peared to exert a synergistic antiproliferative effect. Simi-
larly, in the atherosclerotic rabbit iliac model, cilazapril 
(5 mg/kg per day) reduced the incidence of restenosis after 
balloon dilation (148). In contrast, Lam et al. (149) found no 
benefit of high dose cilazapril (20 mg/kg, twice a day) in the 
porcine carotid angioplasty model. Further data on the 
clinical efficacy of angiotensin-converting enzyme inhibition 
will be available in the near future from a large, multicenter 
cilazapril trial. However, the doses used in this clinical study 
(I to 10 mg, orally twice a day), when adjusted for weight, 
are considerably lower than those used in the experimental 
studies. 
Other agents. Many other agents have been evaluated as 
potential inhibitors of restenosis. Several of these agents 
have been investigated in more than one animal model and in 
humans. Corticosteroids have been shown to inhibit smooth 
muscle cell proliferation in vitro (150) and to inhibit the 
development of stenosis in the atherosclerotic rabbit (151), 
but they do not prevent restenosis after balloon angioplasty 
in humans (124). In in vitro studies colchicine has inhibited 
many of the processes involved in restenosis, including 
smooth muscle cell proliferation, inflammatory cell chemo-
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taxis and secretion of collagen (152), and in the atheroscle-
rotic rabbit, it reduced the incidence and severity of reste-
nosis when given in very high doses (0.2 mg/kg per day) 
(153). In a recently completed clinical study (154), however, 
colchicine therapy (0.6 mg twice a day) was associated with 
a relatively high incidence of side effects but no reduction in 
the incidence of restenosis. 
Several growth factor inhibitors have proved effective in 
animal models and are currently undergoing clinical evalua-
tion. These include trapidil, a platelet-derived growth factor 
antagonist shown to be effective in cell culture (155), rats 
(156), atherosclerotic rabbits (157) and one pilot clinical 
study (158), and angiopeptin, a somatostatin analogue that 
inhibited neointimal proliferation in rat carotid, rabbit iliac 
and nonhuman primate femoral angioplasty models (159) and 
in a heterotopic cardiac transplant model of accelerated 
atherosclerosis (160). Clinical trials of angiopeptin are also 
currently in progress. Finally, lovastatin, which blocks the 
production of mevalonic acid and the synthesis of choles-
terol by inhibiting the enzyme HMG-Co A reductase, has 
been shown to inhibit both cell proliferation in culture 
(161,162) and restenosis after balloon angioplasty in rabbits 
(163). Preliminary data from a small pilot clinical trial (164) 
suggest that lovastatin might also reduce the incidence of 
restenosis in humans. 
Conclusions 
It is evident that no single model of vessel wall injury has 
yet been shown to reliably predict the impact of pharmaco-
logic interventions on the incidence of restenosis in humans. 
Moreover, there appears to be a considerable heterogeneity 
in the susceptibility of the individual models to these inter-
ventions. This is likely to reflect not only the use in most 
models of disease-free rather than atherosclerotic arteries 
and differences in the severity of the vessel injury, but also 
interspecies differences in the healing response to arterial 
injury and intrinsic differences in drug metabolism, lipopro-
tein metabolism and the activity of the fibrinolytic system. It 
may also reflect, in part, an inadequacy of sample size and 
angiographic follow-up in the clinical trials and the consid-
erably lower drug doses used in these studies to avert the 
possibility of systemic side effects. 
Each of the models may be suitable for specific investi-
gations. Cell culture studies remain a very valuable means of 
investigating smooth muscle cell and endothelial cell physi-
ology and may allow rapid screening of multiple potentially 
effective pharmacologic agents. Balloon injury of the rat 
carotid artery or aorta may represent the simplest in vivo 
model for the study of pure smooth muscle cell proliferation. 
In contrast, evaluation of interventional devices requires the 
use of larger animals, including the atherosclerotic rabbit or 
swine, or interposition grafts in peripheral canine arteries. 
Which of the models will most reliably predict the efficacy of 
pharmacologic therapies in humans is not clear. To date, 
with few exceptions, published studies of pharmacologic 
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interventions in the rat and rabbit models have been posi-
tive, but the agents investigated have been ineffective when 
tested in clinical trials. In contrast, although relatively few 
pharmacologic studies have been performed in nonhuman 
primates and pigs, with few exceptions, the reported studies 
in these models have shown no reduction in the severity of 
intimal proliferation. Of all the models studied, perhaps the 
most convenient and most histologically comparable to 
human restenosis is the normal porcine coronary artery with 
an oversized metallic stent. However, no therapeutic ma-
neuver has yet been shown to influence the extent of intimal 
thickening in this model. 
The most important clinical implication of these observa-
tions is that considerable caution should be exercised in the 
extrapolation of positive results of pharmacologic studies in 
experimental models to the likelihood of drug efficacy in 
humans. Ideally, promising new drug therapies should be 
proved effective in several animal models before expensive, 
large scale, clinical trials are initiated. Once therapeutic 
efficacy has been demonstrated in multiple models, clinical 
trials can then be undertaken with appropriate consideration 
of sample size and the adequacy of angiographic follow-up. 
It is hoped that this systematic approach will permit a more 
rapid identification of unequivocally effective pharmacologic 
therapies. 
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